Process Analytical Technology and Process Control in Solid-Dosage Manufacturing - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Process Analytical Technology and Process Control in Solid-Dosage Manufacturing
Industry is moving toward closed-loop control of continuous processing.


Pharmaceutical Technology
Volume 37, Issue 4, pp. 56-61

Other challenges

High equipment costs and restrictions on capital spending are currently barriers to implementing PAT and continuous processing technologies. In addition, revised European regulatory guidance requires refiling of NIR instruments after calibration updates (3). “This new guidance on NIR is very restrictive. It does not allow for changes in raw materials, instrument maintenance, and all the routine occurrences that require calibration maintenance,” notes Hammond.

Real-time release

Although real-time release (RTR) is a goal for industry and for regulators, only a few companies have achieved it as a commercial reality. In RTR, product quality assurance is based on online analysis, and the product is released as it is produced rather than a batch being held while waiting for quality-control testing. RTR could be implemented for batch processing, in that a batch could be released if there were no deviations throughout the batch. In continuous processing, product could be released continually given no deviations. Theoretically, online measurement would identify out-of-specification product and allow it to be segregated or even identify a change in CQAs before the product goes out of specification (4).

A new program, Accelerating Innovative Research (AIR), builds on the C-SOPS infrastructure at Rutgers and is focused on working with existing PAT as well as partnering with companies to move RTR testing technology forward. The program will involve working with large pharmaceutical companies to run specific formulations as case studies in an effort to build up a toolbox of knowledge on how spectroscopic data can be used for RTR testing.

Implementing closed-loop control is a step towards RTR. “Intelligent processes that are proactively controlled to ensure the expected outcome are inherently capable of supporting a RTR strategy. Regulators have always stated that tight control of the unit operations leading up to final product is the best way to ensure quality of the product and enable a RTR filing,” says Hammond, who notes that Pfizer’s Chantix RTR application is now filed in all major markets and most of the rest of world. “The value of RTR has been reduction in laboratory testing. The focus in the future will be on enabling a modern supply chain, with flexible response to a pull from the market, and maintaining lower inventory.”

Many in industry and academia say that continuous manufacturing using online PAT with closed-loop process control and real-time release represent the future of solid-dosage manufacturing. These concepts are part of a “seismic shift in culture change within the pharmaceutical industry, which continues to put the spotlight on manufacturing in a way that has been absent in the past,” concludes Freeman.

References>

1. FDA, Pharmaceutical cGMPs for the 21st Century—Risk-Based Approach: Final Report (Rockville, MD, 2004).

2. FDA, Guidance for Industry: PAT—A Framework for Innovative Pharmaceutical Development, Manufacturing and Quality Assurance (Rockville, MD, 2004).

3. EMA, EMEA/CHMP/CVMP/QWP/17760/2009 Rev2, “Guideline on the use of Near Infrared Spectroscopy (NIRS) by the pharmaceutical industry and the data requirements for new submissions and variations, draft” (London, 2012), www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/02/WC500122769.pdf, accessed March 4, 2013.

4. K. Schoeters, Pharm.Tech. Eur. 23 (2) 20-21 (2011).

FIGURES ARE COURTESY OF GEA PHARMA SYSTEMS


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
27%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
32%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here